Overview

A Study to Evaluate TACE Sequential Tislelizumab as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection

Status:
Not yet recruiting

Trial end date:
2024-12-01

Target enrollment:

Participant gender:

Summary

This is an open label, multi-center, phaseⅡstudy to evaluate the efficacy and safety of TACE sequential tislelizumab as adjuvant therapy in hepatocellular carcinoma (HCC) patients who are at high risk of recurrence after curative resection.

Phase:

Phase 2

Details

Lead Sponsor:

Zhejiang University

Collaborators:

First Hospital of China Medical University
Hainan People's Hospital
Shandong Cancer Hospital and Institute
The Affiliated Hospital Of Southwest Medical University
Tianjin Third Central Hospital